The pay-for-delay ruling is in. That means legal experts and industry analysts are poring over the decision, trying to assess its consequences. Any consensus? By eschewing the Federal Trade Commission's position--that patent-settlement payments should be assumed anticompetitive--the Supreme Court left pharma some leeway. That's better than it might have been. But the choice also leaves a lot of uncertainty on the table. Here's a roundup of opinions and commentary >>
It is Pfizer that will get another chance to knock down an Alabama Supreme Court ruling on the safety of generic drugs, but it stands in for the entire drug development industry that wants to see the the ruling reversed.
Ranbaxy Laboratories has been through a boatload of turmoil this year, but the CEO of India's largest generic drugmaker comes off as unfazed. In fact, he is touting big plans in the U.S. for the company.
A new AARP study worries that Pfizer's aggressive use of price hikes, pay-for-delay deals, and discounts and coupons when Lipitor faced generic competition will become the blueprint for the industry.
Amgen was delivered a nasty surprise about its superblockbuster Enbrel this week when a new study found that a cocktail of generics already on the market was as effective at treating rheumatoid arthritis.
Indian drugmakers have faced compulsory licenses, parochial attitudes about patents and expanded price controls, and government actions. But when citizens in India are unhappy about how drugmakers are acting, they have tools to wield as well, and India's generic giant Ranbaxy Laboratories has just become a target.
Last week, Endo Health Solutions said two of its top officers were leaving, no explanations offered. Today, we have a possible reason: the wholesale restructuring of the company.
AstraZeneca has gotten mixed results in a lawsuit agreement as it continues to try to hold generics at bay in the U.S. for its blockbuster stomach drug Nexium. It said today that it has reached a legal settlement in its patent fight with Hanmi Pharmaceutical and its marketing partner Amneal Pharmaceuticals.
Regulators in both the U.S. and the U.K. have been cracking down on pay-for-delay deals in recent months, with the issue going before the U.S. Supreme Court in March. Now, it seems, EU regulators will join them. The EU's anti-trust regulator, is set to fine 9 generic drugmakers for accepting money to keep their low-cost products off the market.
After almost two years of discussions and dealmaking, Fujifilm and Dr. Reddy's Laboratories have called off their plot to team up on generics in Japan.